Prime SMA Performance Summary – June 2022

Over the course of the pandemic central bankers spent considerable time reassuring investors what might lie ahead in terms of both interest rates and inflation being prudently anchored.

Alas, the glide path back to a ‘goldilocks’ economy assumed that inflation would be transitory in nature. In the end, inflation has prevailed. Now the dolorous combination of errant inflation and an unwelcome slowing of economic growth is the central challenge. 

Investors are now focused not on what the shape of the recovery will be (V,L,W), rather whether the forthcoming downturn will be soft, hard or finely balanced. What is evident is that foretelling the outcome is unknowable. Our working assumption is that heightened vigilance is warranted, with a portfolio layered with a combination of industry leaders that have exhibited greater resilience through economic cycles. The hallmarks of durable earnings and conservatively financed balance sheets remains the course of the day. In times of heightened uncertainty industry leaders in vital industries provides a safer harbour, and ideally the true industry leaders can enhance their competitive advantage in times of economic duress. 

While there may be a cascade of adverse factors to navigate, there has been the silver lining of the reopening of international borders that has allowed us to return to visiting companies with face-to-face meetings in the jurisdictions in which they operate. Many of the ASX200 companies we invest in have significant operations abroad. Indeed, first- hand experience of meeting industry participants in their local markets has provided invaluable insights into our understanding of companies and industries. We recently returned from the UK and Europe conducting meetings across banking, healthcare, logistics, and mining sectors, our key observations were: 

Brambles – Pricing & surcharge mechanisms in contracts has been an effective tool in passing through cost inflation. Demand & pallet scarcity providing pricing power for Brambles. Longer inventory cycle remains an ongoing risk as companies are holding onto pallets longer and lead to ongoing pallet shortages, however, BXB has not seen a collapse in demand. 

CSL & Healthcare – After two years of supply disruption, now witnessing industry wide recovery in plasma supply volumes with structural demand drivers for the plasma therapies in place. Higher collections improving unit economics with meaningful margin uplift expected in FY23. Private healthcare market coming back strongly in the UK as backlog for GP & NHS services at near record levels. 

Mining – Across the mining industry do not underestimate how difficult it is to bring on new supply in either brownfield or greenfield development. Scarcity of supply and underinvestment will a key challenge for decarbonisation.  Mining industry remains disciplined on capex, debt and focused on shareholder returns.  

Portfolio Performance Figures

Risk Profile Portfolio Performance Figures as at 30 June 2022

Post-Franking Credits

Prime SMA – Model Portfolio Performance Figures as at 30 June 2022

Post-Franking Credits

About the Portfolio

Portfolio Objective
To achieve capital growth with moderate tax-effective income via franked dividends through investment in listed Australian securities.

Model Portfolio
The Model Portfolio is managed by selecting primarily those securities with moderate growth potential but robust cash-generating capacity. These securities are expected to deliver an above-market average income yield, together with a relatively moderate level of capital growth. The portfolio benchmark is the S&P/ASX200 Accumulation Index.

The information in this article contains general advice and is provided by Primestock Securities Ltd AFSL 239180. That advice has been prepared without taking your personal objectives, financial situation or needs into account. Before acting on this general advice, you should consider the appropriateness of it having regard to your personal objectives, financial situation and needs. You should obtain and read the Product Disclosure Statement (PDS) before making any decision to acquire any financial product referred to in this article. Please refer to the FSG for contact information and information about remuneration and associations with product issuers. This information should not be relied upon as a substitute for professional advice, and we encourage you to seek specific advice from your professional adviser before making a decision on the matters discussed in this article. Information in this article is current at the date of this article, and we have no obligation to update or revise it as a result of any change in events, circumstances or conditions upon which it is based.


A unique and personal service approach and support for all your business advisory and personal wealth management needs

Request a consultation

A unique and personal service approach to support all your business advisory and personal wealth management needs.

Request a consultation